Back to results
US 12,691,096 B2Granted
Drug-controlled systems and uses thereof
AssigneeTrustees of Boston University
InventorsJohn T. Ngo, Mary Dunlop, Elliot Parker Tague, Nathan Michael Tague, Alexander Michael Marzilli
Life of this patent
Estimating the term…
Abstract
The technology described herein is directed to polypeptide systems using drug-controlled peptide docking domains and cognate docking domain-binding peptides and their use to control cellular signaling, activity, and/or gene expression.
Claims5
A system comprising:
- a) a first polypeptide which is a transmembrane polypeptide, the first polypeptide comprising:
- i) an extracellular receptor, wherein the extracellular receptor is LaG17;
- ii) an extracellular localization domain, wherein the extracellular localization domain is CD8a;
- iii) a Notch receptor regulatory domain (NRR), wherein the NRR has a sequence that is at least 95% identical to SEQ ID NO:
- 190 or 191;
- iv) a Notch transmembrane domain;
- v) a cognate docking domain-binding peptide, wherein the cognate docking domain-binding peptide is CP5-46-4D5E;
- and
- vi) a first member of a pair of activity-complementing domains;
- and
- b) a second polypeptide comprising:
- i) a drug-controlled peptide docking domain, wherein the drug-controlled peptide docking domain is hepatitis C virus (HCV) nonstructural protein 3 (NS3);
- and
- ii) a second member of the pair of activity-complementing domains,
- wherein the first and second member of the pair of activity-complementing domains comprises a Gal4 DNA-binding domain and a transcriptional effector domain, respectively.
12 more elements
Dependencies are inferred from the claim text.